Marker Therapeutics downgraded by Roth Capital with a new price target

2/17/22 6:14:24 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Roth Capital downgraded Marker Therapeutics from Buy to Neutral and set a new price target of $1.00 from $3.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MRKR

Date	Price Target	Rating	Analyst
3/5/2025	$8.00	Buy	Canaccord Genuity
2/17/2022	$3.00 → $1.00	Buy → Neutral	Roth Capital